Us Gastric Cancer Diagnostics Market Size, Share and Outlook - Growth Analysis Report and Forecast Trends 2026-2030

The North American gastric cancer diagnostics market encompasses test kits, instruments, reagents, and associated services used to detect, characterize, and monitor gastric malignancies. The broader North American market is estimated at approximately $571 million in 2025, with the U.S. representing the dominant share of that regional total at roughly $493 million in the same period. Both regional and U.S. sub-markets are on similar growth trajectories, each expected to nearly double in value by the early 2030s.

• •Global gastric cancer diagnostics market valued at approximately $1.3 billion in 2026, on track to reach roughly $2.2 billion by 2033
• •North America estimated at ~$571 million in 2025, projected to reach ~$1,009 million by 2033
• •U.S. market estimated at ~$493 million in 2025, projected to reach ~$897 million by 2033 at a 7%-7.4% CAGR

The primary growth catalyst is the rising global and domestic prevalence of gastric cancer, which increases the volume of diagnostic procedures performed annually. Advances in endoscopic imaging, biomarker-based assays, and liquid biopsy technologies are expanding the diagnostic toolkit beyond traditional histopathology. An aging U.S. demographic, alongside greater awareness and earlier referral patterns, further sustains demand for screening and confirmatory diagnostic services.

• •Rising incidence of gastric cancer globally, including among U.S. populations, drives higher test volumes
• •Technological progress in endoscopy, molecular diagnostics, and biomarker panels enables earlier and more accurate detection
• •Aging population demographics and improved screening protocols support sustained demand growth

The market is broadly segmented by test type, including endoscopy-based procedures, biopsy and histopathology, imaging diagnostics, and molecular or biomarker-based assays, with molecular testing representing one of the fastest-growing sub-segments. Within North America, the U.S. dominates regional market value, while Canada accounts for a smaller but growing share. North America collectively holds a substantial portion of the global market, though Asia-Pacific leads in absolute gastric cancer case volume.

• •Key test categories: endoscopy/upper GI endoscopy, biopsy/histopathology, imaging (CT, PET), and molecular/biomarker assays
• •U.S. accounts for the majority of North American market value; Canada represents a smaller secondary market within the region
• •North America commands a significant global market share, but Asia-Pacific exceeds it in diagnostic test volume due to higher gastric cancer incidence

Who are the notable companies in the industry?

I've reviewed the research text carefully, and **Abbott Laboratories is not mentioned anywhere in it.** The text covers market size, CAGR figures, technological trends (liquid biopsies, NGS, AI-based imaging, endoscopy techniques), and a nonprofit (Hope for Stomach Cancer), but it does not name any specific companies or describe their products or roles. Because your instruction requires that any descriptor for a named company be drawn **only** from the research text, I cannot fabricate details about Abbott Laboratories (e

• •Market structure is moderately fragmented with a coexistence of large diversified players and smaller specialty test manufacturers
• •Competitive technology routes include endoscopic imaging platforms, immunoassay-based biomarker tests, molecular PCR diagnostics, and NGS-based panels
• •Regional manufacturing and R&D capacity is concentrated in the United States, Europe, and East Asian markets with strong healthcare infrastructure

What are the recent trends and outlook?

The market outlook through 2033 remains strongly positive, with consensus CAGR estimates in the 7%-10% range across North American forecasts. Liquid biopsy and circulating tumor DNA technologies are emerging as high-potential growth areas, offering less invasive alternatives to traditional tissue-based diagnostics. Regulatory pathways and reimbursement dynamics in the U.S. will continue to shape adoption rates for new diagnostic entrants and novel assay types.

• •Market expected to maintain a 7%-10% CAGR through the early 2030s, driven by technology adoption and rising disease prevalence
• •Liquid biopsy and circulating tumor DNA-based diagnostics represent a significant emerging opportunity within the gastric cancer testing portfolio
• •U.S. regulatory and reimbursement frameworks will play a key role in determining the pace of adoption for next-generation diagnostic technologies